Taysha Gene Therapies Inc’s recently made public that its 10% Owner Manning Paul B acquired Company’s shares for reported $2.06 million on May 30 ’25. In the deal valued at $2.75 per share,750,000 shares were bought. As a result of this transaction, Manning Paul B now holds 2,841,704 shares worth roughly $6.76 million.
BMO Capital Markets initiated its Taysha Gene Therapies Inc [TSHA] rating to an Outperform in a research note published on June 27, 2024; the price target was $5. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in early April with a ‘”an Overweight”‘ rating. Jefferies also remained covering TSHA and has decreased its forecast on February 01, 2023 with a “Hold” recommendation from previously “Buy” rating. Morgan Stanley revised its rating on January 27, 2023. It rated TSHA as “an Equal-weight” which previously was an “an Overweight”.
Price Performance Review of TSHA
On Friday, Taysha Gene Therapies Inc [NASDAQ:TSHA] saw its stock fall -1.24% to $2.38. Over the last five days, the stock has lost -3.25%. Taysha Gene Therapies Inc shares have fallen nearly -3.45% since the year began. Nevertheless, the stocks have risen 37.57% over the past one year. While a 52-week high of $3.31 was reached on 05/21/25, a 52-week low of $1.05 was recorded on 04/09/25.
Levels Of Support And Resistance For TSHA Stock
The 24-hour chart illustrates a support level at 2.33, which if violated will result in even more drops to 2.27. On the upside, there is a resistance level at 2.45. A further resistance level may holdings at 2.53.
How much short interest is there in Taysha Gene Therapies Inc?
A steep rise in short interest was recorded in Taysha Gene Therapies Inc stocks on 2025-06-13, growing by 7.04 million shares to a total of 33.27 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 26.24 million shares. There was a rise of 21.15%, which implies that there is a positive sentiment for the stock.
